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Abstract. The diagnosis of idiopathic normal pressure hydrocephalus (iNPH) is sometimes complicated by concomitant
Alzheimer’s disease (AD) pathology. The purpose of the present study is to identify an iNPH-specific cerebrospinal fluid (CSF)
biomarker dynamics and to assess its ability to differentiate iNPH from AD. Total tau (t-tau), tau phosphorylated at threonine
181 (p-tau), amyloid- (A) 42 and 40, and leucine-rich -2-glycoprotein (LRG) were measured in 93 consecutive CSF samples
consisting of 55 iNPH (46 tap test responders), 20 AD, 11 corticobasal syndrome, and 7 spinocerebeller disease. Levels of t-tau
and p-tau were significantly decreased in iNPH patients especially in tap test responders compared to AD. Correlation was
observed between Mini-Mental State Examination scores and A42 in AD (R = 0.44) and mildly in iNPH (R = 0.28). Although
A42/40 ratio showed no significant difference between iNPH and AD (p = 0.08), the levels of A40 and A42 correlated positively
with each other in iNPH (R = 0.73) but much less in AD (R = 0.26), suggesting that they have discrete amyloid clearance and
pathology. LRG levels did not differ between the two. Thus, our study shows that although CSF biomarkers of iNPH patients
can be affected by concomitant tau and/or amyloid pathology, CSF t-tau and p-tau are highly useful for differentiation of iNPH
and AD.
Keywords: Alzheimer’s disease, amyloid-, analysis of covariate, idiopathic normal pressure hydrocephalus, leucine-rich -2-
glycoprotein, Mini-Mental State Examination, tap test, tau phosphorylated at threonine 181, total tau
∗Correspondence to: Shun Shimohama, Department of Neurol-
ogy, School of Medicine, Sapporo Medical University, Address:
South 1, West 16, Chuo-ku, Sapporo 060-8543, Japan. Tel.: +81 11
611 2111; Fax: +81 11 622 7668; E-mail: shimoha@sapmed.ac.jp.
INTRODUCTION
Idiopathic normal pressure hydrocephalus (iNPH)
is a neurological disease that usually develops in the
elderly with a typical triad (i.e., gait instability, urinary
incontinence, and cognitive dysfunction [1]). Neu-
roradiologically, iNPH is characterized by enlarged
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ventricles, widening of cortical sulci, and tightening
of parasagittal upper convexity. Impairment of cere-
brospinal fluid (CSF) clearance has been thought to be
the main cause of the disease, and the symptoms can
be alleviated by appropriate shunt surgery. Therefore,
precise diagnosis of iNPH is of importance.
In practice, the diagnostic differentiation of iNPH
from other neurodegenerative disorders can be
difficult. For example, differentiating iNPH from
Alzheimer’s disease (AD) is difficult when the cog-
nitive function of the patient is highly impaired.
Cognitive impairment due to iNPH initially presents
as frontal lobe dysfunctions with deficits in attention,
execution, and thinking. In an advanced stage of iNPH,
short-term memory is impaired like that in AD. In
other instances, differentiating iNPH from neurobe-
havioral disorders, such as Parkinson’s disease and
corticobasal syndrome (CBS), can be challenging. The
gait of iNPH patients is characterized by small-steps
and magnet-like features, resembling the parkinsonian
gait. Evaluating the efficacy of anti-parkinsonian drugs
might be helpful for the diagnosis, but it is not always
available. Some iNPH patients are reported to have
coexisting AD pathology and sometimes CBS [2, 3]. In
these cases, the efficacy of shunt surgery is limited and
temporary, and surgical treatment cannot prevent the
progressive clinical course of the comorbid diseases.
Tap test (TT) is useful for the diagnosis of iNPH,
but the diagnosis is difficult in TT non-responders
(NRs). Moreover, certain TT responders (Rs) under-
gone shunt surgery may still go through a progressive
clinical course, despite the shunt surgery. The com-
bination of neurological examination, neuroimaging
study, and TT is sometimes not sufficient for a clear
diagnosis. Additionally, quantitative estimates of over-
lapping AD pathology are almost impossible to assess
with these clinical examinations. Thus, a biomarker is
required in order to improve diagnostic accuracy and
evaluation of iNPH.
Levels of total tau (t-tau), tau phosphorylated at
threonine 181 (p-tau), and amyloid- (A) are so far
established as CSF biomarkers for AD. In previous
reports, the levels of t-tau and p-tau are elevated and
the A42/40 ratio is decreased in CSF from AD patients
[4–7]. On the other hand, an agreement on changes
in CSF tau has not been established in iNPH patients.
Previous studies show various results of CSF tau levels
in iNPH in comparison to normal subjects: increased
[8], decreased [9], and not changing [2]. However,
CSF tau in iNPH patients is at least lower than that
in AD. Another study showed that CSF A42 is also
decreased in iNPH as in AD [8]. Further, leucine-rich
-2-glycoprotein (LRG) is reported to be highly ele-
vated in iNPH and is believed to be an iNPH-specific
candidate biomarker in CSF [10, 11].
Based on this evidence, we measured these CSF
biomarkers and tried to find correlations between each
biomarker level and the clinical symptoms in iNPH.
MATERIALS AND METHODS
Subjects
The study was undertaken in patients with iNPH,
AD, and other neurodegenerative diseases. Participants
were enrolled from 2009 to 2012 from four hospitals
in Japan: Kyoto University Hospital (Hp.), Saiseikai
Nakatsu Hp., Kitano Hp., and Tenri Yorozu Hp. A total
of 93 consecutive CSF samples were collected in this
study (55 iNPH, 20 AD, 11 CBS, and 7 spinocerebellar
degeneration (SCD)). The demographics and clinical
characteristics of subjects in each group are shown in
Table 1.
Written informed consent for this study was
obtained from each patient. Each patient underwent
a standardized neurological evaluation. iNPH patients
who fulfilled the diagnostic criteria of probable iNPH
by the guidelines were selected including ventricu-
lomegaly with Evans index (EI) >0.3 on a computed
tomography imaging study [12]. All of the iNPH
patients underwent TT, and TT Rs was defined as one
whose walking speed increased more than 10%. Those
who did not respond were defined as NRs. Among the
55 iNPH patients, 46 (83.6%) were Rs (Table 1). An
AD diagnosis was based on current international clini-
cal criteria [13]. Each iNPH and AD patient was scored
with the Mini-Mental State Examination (MMSE).
Biomarker levels in CSF samples (t-tau, p-tau,
Aβ42/40 ratio, LRG)
Levels of t-tau, p-tau, A42/40 ratio, and LRG
in the CSF were measured with an enzyme-linked
immunosorbent assay according to the manufacturer’s
protocol; Tau (Total) Human ELISA Kit - Novex,
Phospho-Tau (181P) - Innotest, Human Amyloid  (1-
42) Assay Kit - IBL, Human Amyloid  (1-40) Assay
Kit - IBL, and Human LRG Assay Kit - IBL.
Statistical analyses
Comparisons among groups were performed using
Chi-square test. Analysis of covariance (ANCOVA)
was additionally used to compare the levels of each
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biomarker between iNPH and AD on assessments after
adjustment for each individual MMSE score. Opti-
mal sensitivity and specificity of each biomarker were
determined by the receiver operating characteristic
(ROC) curve analysis. Results are indicated as median
and 25th–75th percentile. Statistical significance was
defined at p < 0.05.
RESULTS
The CSF biomarker scores of each group are shown
in Fig. 1 and Table 1. ROC analysis results of each
biomarker for differentiating iNPH from AD are shown
in Fig. 2 and Table 2.
Levels of t-tau and p-tau (pg/ml) were significantly
lower in iNPH patients than those in AD patients
(p < 0.0001, p < 0.0001, respectively) (Fig. 1a, b).
These differences had great deals of diagnostic accu-
racies, with the area under the curves (AUC) 0.90 and
0.91, with optimal threshold values of 766 (sensitiv-
ity 75%, specificity 98%) and 24.4 (sensitivity 95%,
specificity 74%), respectively (Fig. 2). In the iNPH
patients, levels of t-tau and p-tau were lower in the Rs
subgroup than in the NRs subgroup (p < 0.05, p = 0.06,
respectively). Levels of t-tau in Rs were lowest with
significance compared with rest of the groups (Fig. 1a,
b). The levels of t-tau and p-tau strongly correlated with
each other in AD (R = 0.90) and iNPH NRs (R = 0.91)
Fig. 1. Box plots of each CSF biomarker in the studied group; t-tau (a), p-tau (b), A42/40 ratio (c), and LRG (d). Horizontal lines within boxes
show median values, boxes show upper and lower interquartile (IQ) ranges, whiskers indicate the 1.5 times IQ, a cross (x) in the figure indicate
outlier values (1.5 times IQ). ∗p < 0.05, ∗∗p < 0.001.
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Fig. 2. ROC curve analysis for each CSF biomarker for differentia-
tion of iNPH from AD.
Table 2
Comparison of CSF biomarkers between patients with iNPH and
AD: ROC analysis
t-tau p-tau A42/40 LRG
AUC 0.90 0.91 0.71 0.60
Cutoff value 766 pg/ml 24.4 pg/ml 0.038 35.8 ng/ml
Sensitivity 75% 95% 53% 100%
Specificity 98% 74% 94% 28%
iNPH, idiopathic normal pressure hydrocephalus; AD, Alzheimer’s
disease; t-tau, total tau; p-tau, phosphorylated tau; A, amyloid-
; LRG, leucine-rich -2-glycoprotein; ROC, receiver operating
characteristic analysis; AUC, area under the curve.
subgroups compared to iNPH Rs (R = 0.54) subgroup
(Fig. 3a).
The A42/40 ratio was higher in iNPH patients than
in AD patients (p < 0.01). Using ANCOVA with diag-
nostic group of iNPH and AD as a factor, and MMSE
scores as a covariate, the diagnostic group did not show
impact on the levels of A42/40 ratio (p = 0.08) (Fig. 1c,
Table 1). MMSE scores of AD patients were correlated
with the levels of A42 (R = 0.44) and inversely cor-
related to the levels of t-tau (R = 0.37), whereas the
iNPH group showed less clear correlations between
MMSE scores and the levels of A42 (R = 0.28). In
iNPH group, MMSE scores and the levels of t-tau were
not inversely correlated as in AD (R = 0.17) (Fig. 4a,
b). The levels of A40 and A42 showed strong cor-
relations in the iNPH (R = 0.73) and CBS (R = 0.94)
groups, while they showed less clear correlation in
Fig. 3. Correlation between t-tau and p-tau in iNPH Rs, NRs, and
AD (a). Correlation between A40 and A42 in iNPH, AD, and CBS
(b).
the AD group (R = 0.26) (Fig. 3b). LRG levels did not
differ among iNPH, AD, CBS, and SCD (Fig. 1d).
DISCUSSION
In this study, t-tau and p-tau levels were highly
decreased in iNPH patients than in AD patients. Lev-
els of t-tau and p-tau showed a strong correlation each
other in AD, while they did not in iNPH Rs sub-
group. Given that these two pathological conditions
are distinguishable by differential biomarker profiles,
iNPH appears to have a unique tau-negative pathology
that differs from AD. In iNPH, an excessive volume
of CSF, mainly accumulating in the cerebral ventri-
cles and subarachnoid space of cortical sulci, might
dilute the concentration of tau in CSF, which might
account for the lower tau values. In iNPH Rs, t-tau
levels were lower than those in NRs. Therefore, iNPH
patients who have lower t-tau concentration in CSF
might be the better candidates for surgical treatment.
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Fig. 4. Correlations between the MMSE score and t-tau (a) and A42
(b) in iNPH and AD.
The iNPH patients with higher t-tau and p-tau levels
might have stronger overlaps of tau pathology such as
AD. Another possibility is that the iNPH itself has pro-
gressed to an irreversible stage due to a longer clinical
course, leading to severe white matter degeneration and
neurodegeneration with higher average t-tau levels in
CSF. Thus, iNPH patients with higher CSF t-tau val-
ues might have a progressive clinical course even after
shunt surgery.
CSF A42/40 ratio in iNPH patients seemed to be
significantly higher than in AD patients. We found a
correlation between MMSE scores of iNPH patients
and the levels of A42, which might suggest that the
cognitive function of iNPH patients is affected by the
preclinical stages of AD [14]. As there was a non-
negligible MMSE score difference between the iNPH
and AD groups (p = 0.001), we used ANCOVA with
MMSE scores as a covariate for the evaluation of CSF
A42/40 ratio between the two groups, resulting that the
CSF A42/40 ratio does not statistically differ between
iNPH and AD patients.
Interestingly, the profile in the levels of A40 and
A42 in the AD group was different from those in the
iNPH and CBS groups. In the groups of iNPH and
CBS, the levels of A40 and A42 showed positive
correlation; individuals with high A40 value in the
CSF showed high A42 value as well. However, this
correlation was not so clear in AD group. This might be
explained by the preference for A42 deposition in the
cerebral cortex of AD brain. The profile of A40 and
A42 in iNPH group was similar to that in CBS group.
This suggests that the amyloid pathology of iNPH as
a group is discrete from that of AD as a group. The
pathophysiology of iNPH does not seem to favor A42
deposition like AD.
The levels of LRG in CSF are reported to be
increased in iNPH patients [11]. However, LRG levels
were not different between iNPH and AD patients in
this study. We also evaluated LRG levels between Rs
and NRs iNPH patients, but could not find any differ-
ence. Since LRG is reported to be a potential biomarker
for the diagnosis of iNPH, larger size of studies are
required to evaluate the previously reported results.
The goal of our study is to search for useful CSF
biomarkers to differentiate iNPH from AD. How-
ever, the comparison of CSF biomarker between iNPH
and age-matched healthy control subjects was more
ideal. Unfortunately, because the subjects were elderly
patients, access to CSF samples from pure normal age-
matched control subjects were limited in this study.
The groups compared as control consisted of CBS and
SCD. We chose to compare CBS patients because their
levels of CSF tau are reported to not be increased [15],
and they are not specific for amyloid pathology. There-
fore, we assume that the quality of the compared groups
including CBS were suitable for investigation of the
biomarkers described above.
As iNPH NRs had higher CSF t-tau compared to
Rs, and the cognitive function of iNPH patients was
mildly associated with the level of CSF A42, it is true
that some individuals in iNPH overlap with other neu-
rodegenerative diseases, especially AD. The degree of
overlapping pathology, which is clinically ineludible
but difficult to be estimated, might be reflected by CSF
biomarkers to a certain extent. The overlaps in CSF
biomarker profile between these distinct pathological
conditions may suggest that the pathophysiology of
each iNPH individual is sometimes mixed and hetero-
geneous.
However, in conclusion, our results show that
t-tau and p-tau were equally and highly useful CSF
biomarkers for differentiating iNPH from AD, even
though they might not specifically reflect the iNPH
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pathophysiology. In addition, as in the two groups, the
difference of A profile shows discrete pathologies.
The above biomarkers reveal that iNPH has a different
CSF biomarker profile from AD. These CSF biomark-
ers could improve the diagnostic accuracy of iNPH,
especially iNPH Rs with less tau pathology. They could
also influence selection of the treatment course and
could predict the prognosis of patients. The quest for
more specific CSF biomarkers for iNPH is ongoing,
and further studies should be conducted with in a larger
population of patients.
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